Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 975,621
  • Shares Outstanding, K 26,361
  • Annual Sales, $ 9,540 K
  • Annual Income, $ -72,150 K
  • 60-Month Beta 2.71
  • Price/Sales 104.24
  • Price/Cash Flow N/A
  • Price/Book 3.25
Trade ARCT with:

Options Overview Details

View History
  • Implied Volatility 131.17%
  • Historical Volatility 94.55%
  • IV Percentile 95%
  • IV Rank 77.61%
  • IV High 147.80% on 08/03/21
  • IV Low 73.54% on 06/17/21
  • Put/Call Vol Ratio 0.08
  • Today's Volume 265
  • Volume Avg (30-Day) 827
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 6,520
  • Open Int (30-Day) 8,195

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -1.81
  • Number of Estimates 4
  • High Estimate -0.80
  • Low Estimate -2.31
  • Prior Year -1.25
  • Growth Rate Est. (year over year) -44.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.84 +9.37%
on 11/23/21
46.31 -20.08%
on 11/04/21
-8.57 (-18.80%)
since 11/03/21
3-Month
33.84 +9.37%
on 11/23/21
58.09 -36.29%
on 09/09/21
-17.27 (-31.82%)
since 09/03/21
52-Week
24.87 +48.81%
on 05/13/21
129.71 -71.47%
on 12/07/20
-62.30 (-62.73%)
since 12/03/20

Most Recent Stories

More News
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -46.43% and -90.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?...

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics Announces Leadership Appointments

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines...

ARCT : 37.01 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 40.48
2nd Resistance Point 39.56
1st Resistance Point 38.28
Last Price 37.01
1st Support Level 36.08
2nd Support Level 35.16
3rd Support Level 33.88

See More

52-Week High 129.71
Fibonacci 61.8% 89.66
Fibonacci 50% 77.29
Fibonacci 38.2% 64.92
Last Price 37.01
52-Week Low 24.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar